SUPRIYA
1 call
Concalls & earnings callsSupriya Lifescience Limited
Every summarised call, newest first. Latest is Q1 FY27, held 14 Aug 2026.
Latest quarter
Q1 FY27 snapshot
Open full brief →Revenue grew 31% year-on-year, but EBITDA margin contracted to 25% due to temporary water scarcity and one-off solar policy costs, though management remains confident in its full-year revenue and margin guidance.
| Metric | This quarter | Change | Five-quarter trend |
|---|---|---|---|
| Revenue | ₹190 Cr | 31% | |
| EBITDA | ₹47 Cr | -8.1% | |
| EBITDA Margin | 25% | — | |
| PAT | ₹24 Cr | — |
Latest guidance
- Revenue target of ~Rs 1,000 crores for FY27 remains on track.
- EBITDA margin guidance of 33% to 35% for FY27 is maintained.
- Expects stronger ramp-up in the second half of FY27.
- Targets a 20% year-on-year CAGR growth trajectory with potential for more.
Said on the Q1 FY27 call.
Filed results
Reported quarterly history
From filed quarterly results. YoY and QoQ compare each metric on the same accounting basis.
| Quarter | Revenue | Net profit (PAT) | Basic EPS |
|---|---|---|---|
| Q3 FY25 | ₹185.65 Cr+32.5% YoY+11.8% QoQ | ₹46.78 Cr+57% YoY+1.4% QoQ | ₹5.82+57.3% YoY+1.9% QoQ |
| Q2 FY25 | ₹166.10 Cr+18.6% YoY+3.4% QoQ | ₹46.15 Cr+93.3% YoY+3.4% QoQ | ₹5.71+92.3% YoY+3.1% QoQ |
| Q1 FY25 | ₹160.63 Cr+21.7% YoY+1.5% QoQ | ₹44.64 Cr+56.6% YoY+20.9% QoQ | ₹5.54+56.5% YoY+20.7% QoQ |
| Q4 FY24 | ₹158.18 Cr+11.2% YoY+12.9% QoQ | ₹36.93 Cr-3.4% YoY+24% QoQ | ₹4.59-3.4% YoY+24.1% QoQ |
| Q3 FY24 | ₹140.07 Cr+33.2% YoY0% QoQ | ₹29.79 Cr+212.9% YoY+24.7% QoQ | ₹3.70+213.6% YoY+24.6% QoQ |
Call history
- Q1 FY27Cautious tone
Revenue grew 31% year-on-year, but EBITDA margin contracted to 25% due to temporary water scarcity and one-off solar policy costs, though management remains confident in its full-year revenue and margin guidance.
- Revenue
- ₹190 Cr31%
- EBITDA
- ₹47 Cr-8.1%